Steroid History: From the Discovery of Testosterone to Modern Anabolic Steroids

The history of anabolic steroids is not the story of a single invention. It is a centuries-long sequence of experiments, hormone discoveries, pharmaceutical innovations, medical treatments, sporting controversies, laws, and increasingly sophisticated drug tests. The modern era took shape in 1935, when several European research groups isolated or synthesized testosterone. Yet its foundations reach back to animal experiments in the eighteenth and nineteenth centuries, while its consequences continue in medicine, competitive sport, online markets, and appearance culture today.

This article follows that development chronologically and separates documented events from stories repeated without strong contemporary evidence. No single scientist “invented steroids,” Dianabol was not the first steroid, and claims that Nazi Germany created anabolic steroids for soldiers remain unsubstantiated.

Medical notice: This article is for education and historical reference only. It does not provide medical advice or instructions for using anabolic-androgenic steroids.

Commercial disclosure: This article does not endorse the nonmedical use, purchase, or sale of anabolic steroids. Add any site-specific financial or affiliate disclosure here before publication.

What Does “Steroid” Mean?

“Steroid” describes a large family of molecules that share a characteristic four-ring carbon structure. The category includes cholesterol, vitamin D-related compounds, corticosteroids such as cortisol, sex hormones such as testosterone and estradiol, and many synthetic medicines. These substances can have very different biological effects.

This distinction matters because everyday conversation often treats all steroids as one drug class. Corticosteroids used to control inflammation are not the same as anabolic-androgenic steroids used medically to replace testosterone or misused to increase muscularity and performance. Human growth hormone, insulin, clenbuterol, peptides, and selective androgen receptor modulators are also not anabolic steroids, even when they appear in the same discussions about performance-enhancing drugs.

This history focuses on anabolic-androgenic steroids (AAS): testosterone and synthetic compounds related to it. “Anabolic” refers to tissue-building effects, including increased protein synthesis and muscle growth. “Androgenic” refers to effects associated with male sexual development and characteristics. Scientists spent decades trying to separate these two properties, but no steroid has proved purely anabolic and entirely free of androgenic activity (Kicman, 2008).

Testosterone can simultaneously be a natural hormone, prescription drug, prohibited substance under sports rules, and U.S. controlled substance. Medical approval, anti-doping status, and criminal scheduling answer different questions and are not interchangeable.

Before Testosterone: Early Ideas About the Testes and the Body

In 1786, Scottish surgeon and anatomist John Hunter transplanted a rooster’s testis into the abdominal cavity of a hen. The experiment is frequently cited as an early attempt at tissue transplantation and as part of the intellectual prehistory of endocrinology. Hunter could not identify a hormone, but the work helped frame a durable question: could reproductive tissue influence distant parts of the body?

German physiologist Arnold Adolph Berthold supplied a more persuasive answer in 1849. He removed the testes of young roosters and observed the expected loss of male characteristics. When he transplanted testes back into the abdominal cavity, some of those characteristics returned. The transplanted organs had no restored nerve connection, leading Berthold to propose that the testes released something into the blood. His work is now regarded as a foundational demonstration of internal secretion—what would later be called hormonal action (Nieschlag & Nieschlag, 2014).

Berthold did not isolate testosterone, but his work showed that an organ could communicate chemically with distant tissues rather than acting only through nerves or direct anatomical connections.

Brown-Séquard and the First Testosterone-Rejuvenation Sensation

In 1889, the prominent physiologist Charles-Édouard Brown-Séquard, then in his seventies, reported that he had injected himself with extracts made from dog and guinea-pig testes. He claimed temporary improvements in strength, stamina, mental performance, and bodily functions. His report attracted international attention and inspired a market for so-called organotherapy: attempts to treat illness or aging with extracts of animal glands.

The experiment popularized the therapeutic promise of gonadal secretions but did not establish the efficacy of testosterone. The extracts likely contained too little active hormone to explain his dramatic claims. Later historians have treated the episode as an early illustration of expectancy and placebo effects, although its contents cannot now be reconstructed with certainty (Cussons et al., 2002). It also introduced a recurring pattern: promises of youth and vitality moved faster than the science.

From Gland Extracts to Steroid Chemistry

The decisive advances required chemistry, not simply transplantation or crude extracts. During the early twentieth century, researchers began isolating sex hormones from enormous quantities of animal tissue and human urine. These projects demanded industrial-scale collection, improved purification methods, and collaboration between academic laboratories and pharmaceutical companies.

In 1931, German chemist Adolf Butenandt isolated androsterone, a weak androgenic steroid, from thousands of liters of male urine. The achievement demonstrated that a male sex-hormone-related compound could be purified and chemically characterized. Androsterone was not testosterone, but its isolation narrowed the search and accelerated work on the structure of androgenic hormones.

Chemists were also clarifying the common ring structure of cholesterol, bile acids, adrenal hormones, and sex hormones. The word steroid entered scientific usage in the mid-1930s. This wider history makes “the first steroid” an inherently slippery phrase: steroid molecules occur naturally, and several steroid hormones were isolated before testosterone.

1935: Testosterone Is Isolated, Named, and Synthesized

The landmark year in testosterone history was 1935. Multiple research teams working in a competitive European pharmaceutical environment reached related breakthroughs within months of one another.

A group associated with Organon in the Netherlands—including Karoly David, Ernst Laqueur, E. Dingemanse, and J. Freud—isolated a crystalline androgen from bull testes and introduced the name testosterone, combining references to the testis, sterol chemistry, and a ketone group. In Germany, Adolf Butenandt and G. Hanisch reported a chemical synthesis of testosterone. In Switzerland, Leopold Ružička and Albert Wettstein, working in the CIBA research environment, independently described another synthesis.

These overlapping achievements make the popular question “Who invented testosterone?” misleading. Testosterone is a hormone produced naturally by the human body, not a molecule created from nothing by one inventor. The hormone was isolated, identified, named, and synthesized through the work of several scientists and industrial laboratories. It is more accurate to credit a network of researchers than to attach the discovery to one person (Freeman et al., 2001; Nieschlag & Nieschlag, 2014).

Synthesis freed researchers from relying on tiny tissue extracts. It enabled controlled experiments, practical medicines, and deliberate molecular modification—marking the beginning of the modern anabolic-steroid era.

The 1939 Nobel Prize—and What It Did Not Mean

In 1939, the Nobel Prize in Chemistry was divided between Butenandt and Ružička. The official motivations require careful wording: Butenandt was recognized for his work on sex hormones, while Ružička was honored for work on polymethylenes and higher terpenes. Their research contributed to the chemistry that made steroid hormones understandable and producible, but the prize was not simply awarded “for inventing steroids.”

Modern steroid science therefore arose from cumulative work in endocrinology, organic chemistry, physiology, and pharmaceutical manufacturing—not one prize or invention.

Early Testosterone Medicines: Solving the Delivery Problem

Unmodified testosterone is not an ideal medicine when swallowed because the body rapidly metabolizes it. Early pharmaceutical development therefore focused on changing either the molecule or its formulation.

Two approaches became especially important:

• 17β-esterification: Attaching an ester to testosterone’s 17-beta hydroxyl group changes how the drug is released from an injected oil depot. Esters such as testosterone propionate extended activity and made dosing more practical. The ester is eventually removed in the body, releasing testosterone.
• 17α-alkylation: Adding an alkyl group at the 17-alpha position can help a steroid survive first-pass metabolism and remain active by mouth. This convenience came with an important cost: many 17α-alkylated steroids place greater stress on the liver and are associated with hepatotoxicity.

Chemists also modified the steroid rings, altered double bonds, and substituted atoms or chemical groups. These changes affected oral availability, duration, receptor activity, conversion to other hormones, and the balance between anabolic and androgenic effects. Drugs such as methyltestosterone and testosterone propionate appeared during the later 1930s, followed by a growing family of synthetic derivatives in the 1940s and 1950s (Kicman, 2008).

These modifications shifted properties and risks; they did not create an absolutely “safe” or purely muscle-building steroid.

Why Were Anabolic Steroids Originally Developed?

The first clinical purpose of testosterone was hormone replacement, not athletic performance. Physicians explored it for males with absent or impaired testicular function, delayed puberty, and related endocrine conditions. Researchers also investigated whether its protein-building and red-blood-cell effects could help patients with anemia, severe weight loss, burns, trauma, prolonged immobilization, osteoporosis, and recovery from major illness.

During the mid-twentieth century, AAS were tested or prescribed for a wide range of conditions, including aspects of breast-cancer care and hereditary angioedema. Some uses reflected genuine physiological effects; others reflected limited alternatives and weaker evidence standards. Many were later narrowed, abandoned, or replaced.

This is an important limit on historical reasoning: the fact that a drug once had a medical use does not validate every modern claim made for it. Medicine evolves as controlled trials, surveillance, and alternative therapies improve. A 1950s indication is evidence about the history of practice, not automatic proof of present-day safety or efficacy.

Today, a small number of anabolic agents retain legitimate medical roles. FDA-approved testosterone products are intended for specific forms of hypogonadism associated with defined medical conditions, and labeling has changed as evidence and safety reviews have evolved. Approval of one product for one indication does not imply approval of bodybuilding, performance enhancement, or unmonitored anti-aging use. Likewise, a clinician’s lawful prescription is different from nonmedical use or illicit distribution.

What Was the First Anabolic Steroid?

There is no single answer unless the category is defined first.

If anabolic-androgenic steroid includes the body’s own androgen, then testosterone is the foundational AAS and the first one used clinically in modern form. If the question means the first synthetic derivative marketed specifically for a more favorable anabolic-to-androgenic profile, several compounds from the 1950s compete for the label. Norethandrolone, marketed in that decade, is often described as one of the earliest commercial synthetic anabolic steroids.

Methandrostenolone, better known by the trade name Dianabol, was introduced by CIBA in the United States in 1958. It became highly influential because of its oral activity and rapid adoption in strength and bodybuilding circles. But it was not the first steroid hormone, the first testosterone medicine, or necessarily the first synthetic anabolic steroid.

Dr. John Ziegler, Dianabol, and the Soviet Weightlifting Story

American physician John Bosley Ziegler is closely associated with the early use of anabolic steroids in U.S. strength sports. He worked with weightlifters at the York Barbell Club in Pennsylvania and became involved in evaluating testosterone and later methandrostenolone. His name is often linked to Dianabol’s introduction to athletes, but calling him “the inventor of steroids” is wrong. The relevant hormone science, synthetic testosterone, and earlier derivatives all predated his work.

A widely repeated story places a pivotal encounter at the 1954 World Weightlifting Championships in Vienna. According to later accounts, a Soviet team doctor told Ziegler that Soviet lifters were using testosterone. Ziegler then supposedly experimented with testosterone and helped introduce Dianabol as an American response.

The story is plausible in the context of Cold War sport, and it appears frequently in retrospective histories. However, its most dramatic details rely heavily on recollections rather than a strong body of contemporaneous documentation. It should therefore be presented as an influential account, not as an independently proven transcript of events. What is well established is that testosterone and synthetic AAS entered elite strength sports during the 1950s, that Ziegler had a role in their American adoption, and that Dianabol became especially prominent after 1958 (Kanayama & Pope, 2018).

Steroids in Sport During the 1960s and 1970s

Anabolic-steroid use spread through weightlifting, throwing events, American football, powerlifting, and bodybuilding in the 1960s. Information circulated through coaches, team doctors, gyms, personal networks, and informal experimentation. The drugs were prescription products, and their use did not yet carry the same U.S. controlled-substance status that it would acquire decades later.

The expansion had several drivers: gains in lean mass and strength, the value of small competitive advantages, limited impartial medical information, and Cold War pressure to turn sport into a display of national prestige. Secrecy made harms and failures less visible than successful physiques or records.

Bodybuilding gave steroid use a particularly visible cultural home. The sport’s judging standards increasingly favored exceptional muscular size, definition, and leanness. By the 1970s, physiques that were difficult to achieve without pharmacological assistance influenced magazines, films, gyms, and public ideals of the male body. Yet open discussion lagged behind the practice. This gap helped produce a mythology in which drug use was simultaneously common, denied, glamorized, and poorly understood.

Nonmedical use gradually moved beyond elite athletes. Recreational lifters and people motivated primarily by appearance adopted AAS, a trend that became more pronounced from the 1980s onward. Epidemiological research now treats most users not as elite competitors but as predominantly male non-athletes seeking muscularity, leanness, or a particular body image (Kanayama & Pope, 2018).

State-Sponsored Doping in East Germany

One of the best-documented chapters in steroid history is the systematic doping program of the former German Democratic Republic (GDR). From the 1960s through the 1980s, athletes were given performance-enhancing drugs within a state-supported system involving sports officials, physicians, scientists, and security structures. The program later became associated with the bureaucratic designation State Plan 14.25.

Anabolic steroids—particularly Oral-Turinabol—were central to the program. Female athletes and minors were among those exposed, often without meaningful informed consent or accurate information about what they were receiving. Documented consequences included virilization and reproductive, endocrine, hepatic, cardiovascular, and psychological problems. Records recovered after German reunification, combined with testimony and subsequent litigation, made the GDR program far more than rumor or sporting folklore (Franke & Berendonk, 1997).

The program shows why doping cannot always be reduced to an athlete’s private choice: medical authority, national ambition, secrecy, and coercion can combine.

When Did the Olympics Ban Anabolic Steroids?

The shortest accurate answer is that the Olympic prohibition and testing regime developed between 1974 and 1976.

The International Olympic Committee prohibited anabolic steroids in 1974. The formal list and practical implementation evolved through 1975 as laboratories developed workable analytical methods. At the 1976 Montreal Olympic Games, organizers conducted the first Olympic testing program for anabolic steroids. This phased history explains why reputable sources sometimes attach different years to “the ban”: one may refer to the policy decision, another to inclusion or implementation, and another to the first Olympic tests (Fitch, 2008; Hemmersbach, 2008).

Testing had been technically difficult. AAS and their metabolites are present at low concentrations, many resemble natural hormones, and athletes may stop taking short-acting compounds before competition. The emergence of gas chromatography combined with mass spectrometry gave laboratories a much more specific way to separate substances and identify chemical signatures.

Ben Johnson and the Public Turning Point of 1988

Anabolic steroids had produced controversies before 1988, but the Seoul Olympic Games transformed the issue into a global public drama. Canadian sprinter Ben Johnson won the men’s 100-meter final in world-record time, then tested positive for stanozolol, an anabolic steroid. He was disqualified and stripped of the gold medal.

The scandal mattered because it joined several powerful images: the world’s fastest race, an apparently decisive laboratory result, a superstar’s fall, and suspicions that doping extended well beyond one athlete. The subsequent Canadian Commission of Inquiry, led by Justice Charles Dubin, examined drug use across sport and exposed failures involving athletes, coaches, physicians, administrators, and governing bodies.

Johnson’s case did not begin the anti-doping era or prove that every rival was drug-free. Its importance lay in visibility: steroid use became mainstream news, increasing pressure for coordinated rules, testing, and sanctions.

U.S. Steroid Law Before and After 1990

It is inaccurate to say that steroids were “legal until 1990” or “always illegal.” Before 1990, anabolic steroids were regulated as prescription drugs, and conduct such as unlicensed distribution or misbranding could violate federal or state law. They were not, however, scheduled under the federal Controlled Substances Act as anabolic steroids are today.

The Anabolic Steroids Control Act of 1990 placed 27 named anabolic steroids in Schedule III of the Controlled Substances Act and established a federal definition for the category. The law was enacted in 1990, with scheduling taking effect in 1991. Schedule III status imposed controlled-substance rules on manufacture, prescribing, possession, and distribution while preserving legitimate medical use.

Congress revisited the category as supplement markets and chemists introduced prohormones and new compounds designed to fall outside older lists. The Anabolic Steroid Control Act of 2004 added numerous substances, broadened the framework, and specifically excluded dehydroepiandrosterone, or DHEA, from the federal definition. The Designer Anabolic Steroid Control Act of 2014 (DASCA) further strengthened the government’s ability to classify designer steroids and addressed products falsely presented as dietary supplements.

Current federal law defines an anabolic steroid through both chemical relationship and intended pharmacological effect, with specified exclusions for estrogens, progestins, corticosteroids, and DHEA. State rules can add separate requirements or penalties. This legal history is specific to the United States; other countries classify testosterone and related drugs differently.

None of these categories should be confused with sports rules. A substance may be lawfully prescribed to a patient and still be prohibited in competition unless the athlete meets the requirements for a therapeutic use exemption. Conversely, an anti-doping violation is not automatically the same as a criminal offense.

WADA and the Globalization of Anti-Doping

The doping controversies of the 1980s and 1990s exposed fragmented rules among international federations and national authorities. The 1998 Tour de France “Festina affair,” which involved a broader range of performance-enhancing drugs, added urgency to calls for an independent global body.

The World Anti-Doping Agency (WADA) was founded in 1999. Its World Anti-Doping Code and annual Prohibited List created a more harmonized framework across participating sports and countries. Under the current list, S1 Anabolic Agents are prohibited at all times—both in and out of competition. The category covers exogenous AAS as well as prohibited administration of endogenous androgens such as testosterone.

WADA did not eliminate differences in enforcement or resources, but it established a common framework for prohibited substances, testing, laboratories, sanctions, and therapeutic use exemptions. Because its list is updated regularly, current compliance questions require checking the current rules.

Designer Steroids, BALCO, and THG

As tests improved, some suppliers attempted to create or distribute compounds that routine screens did not yet target. The Bay Area Laboratory Co-operative (BALCO) investigation became the defining scandal of this designer-steroid era.

In 2003, a previously unknown sample reached the laboratory led by anti-doping scientist Don Catlin. Researchers identified tetrahydrogestrinone (THG), a potent synthetic anabolic agent that had been used because standard tests were not looking for it. The laboratory synthesized reference material and developed a method to detect it in urine (Catlin et al., 2004).

THG demonstrated a fundamental weakness of list-based screening: a test cannot easily target a compound whose structure is unknown. It also demonstrated the countermeasure. Investigators, whistleblowers, organic chemists, mass-spectrometry specialists, and sports authorities could work together to identify an “invisible” drug and add it to testing programs.

How Modern Steroid Testing Works

Modern laboratories use several complementary approaches rather than one universal steroid test.

Gas chromatography–mass spectrometry (GC-MS) separates volatile derivatives of compounds and identifies them through mass spectra. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) is useful for compounds and metabolites suited to liquid-phase analysis. Researchers have also discovered long-term metabolites that extend the period in which prior use can be detected.

Testosterone creates a special challenge because the body produces it naturally. Isotope-ratio mass spectrometry (IRMS) can sometimes distinguish administered testosterone made from plant-derived pharmaceutical precursors from endogenous hormone by comparing carbon-isotope patterns. Laboratories also examine ratios among testosterone and related urinary steroids.

The steroidal module of the Athlete Biological Passport adds a longitudinal dimension. Instead of relying only on a population-wide cutoff, it tracks an individual athlete’s steroid profile over time and flags changes inconsistent with that person’s established pattern. The result is not a magical lie detector: sample collection, metabolism, genetics, illness, medication, and analytical uncertainty still require expert interpretation. But the approach makes it harder to evade detection simply by staying below a single fixed threshold (Anawalt, 2019).

Stored samples add another layer. Major event organizers can preserve specimens for later reanalysis, allowing newer methods to detect substances or metabolites that older tests missed. History therefore runs backward as well as forward: results and medal tables can change years after a competition.

The Internet, Underground Laboratories, and Appearance Culture

By the late 1990s and 2000s, the internet changed how nonmedical users learned about and obtained anabolic steroids. Discussion boards made specialized vocabulary widely accessible. Online sellers and underground laboratories expanded supply beyond face-to-face gym networks. Social media later accelerated physique comparison, fitness marketing, transformation content, and exposure to highly muscular bodies.

More information did not necessarily mean better information. Online communities can share harm-reduction messages, but they can also normalize use and turn anecdote into apparent expertise. Product reviews cannot establish identity, sterility, or concentration.

The underground market creates risks beyond the pharmacology of the intended drug. Products may be counterfeit, substituted, mislabeled, under- or over-concentrated, contaminated, or produced without sterile controls. Consumers may not know whether a vial or tablet contains the named substance at all. Those uncertainties are one reason historical pharmaceutical data cannot simply be applied to products obtained from an unregulated source.

Appearance is now a major driver. Many users pursue muscularity, leanness, confidence, status, or social-media visibility rather than elite medals. Steroid history is therefore also a history of body image, masculinity, medicine, commerce, and online culture.

Medical Knowledge and the Recognition of Harm

Early enthusiasm outpaced knowledge of long-term risk. Evidence now links nonmedical AAS use to suppression of natural testosterone and sperm production, infertility, sexual dysfunction, gynecomastia, acne, and hair changes. In women, androgen exposure may cause menstrual disruption and virilizing changes, some potentially irreversible.

Other concerns include adverse cholesterol and blood-pressure changes, abnormal heart structure or function, possible major cardiovascular events, and liver injury—especially with oral 17α-alkylated steroids. Effects can also include mood disturbance, depression during withdrawal, dependence, and infection from nonsterile injections (National Institute on Drug Abuse, 2024; Pope et al., 2014).

Risk varies with the compound, exposure, individual, and product quality, but variability is not safety. Legitimate treatment has a different context: a diagnosed condition, regulated product, therapeutic target, screening, and follow-up. Even prescribed testosterone requires an individualized benefit-risk assessment.

Persistent Myths About Steroid History

Myth 1: Nazi Germany invented anabolic steroids

This claim is repeated frequently online, sometimes with vivid stories about testosterone being administered to soldiers for aggression or endurance. Reliable historical scholarship supports major German contributions to sex-hormone chemistry in the 1930s, including Butenandt’s work and the synthesis reported with Hanisch. That is not the same as proof of a systematic wartime soldier-doping program.

The strongest responsible conclusion is that the Nazis did not “invent steroids.” Testosterone emerged from an international scientific and pharmaceutical effort, and the specific military-use stories lack the documentation needed to present them as established fact.

Myth 2: John Ziegler invented steroids

Ziegler was born after the key nineteenth-century endocrine experiments and entered the story after testosterone had been isolated, synthesized, formulated, and prescribed. His importance lies in the early American sports use of testosterone and Dianabol, particularly around strength athletes—not in inventing the hormone class.

Myth 3: Dianabol was the first steroid

Dianabol was introduced in 1958 and became one of the most influential oral AAS in sport. Testosterone medicines and other synthetic derivatives already existed. Calling Dianabol “the first steroid” confuses commercial and athletic prominence with chemical priority.

Myth 4: All steroids are the same

Corticosteroids and anabolic steroids have different principal actions and clinical uses. Within the AAS category, compounds also differ in metabolism, delivery, duration, conversion pathways, and toxicity. Shared membership in a chemical family does not make them interchangeable.

Myth 5: Steroids were either completely legal or completely illegal

Legal status depends on time, jurisdiction, product, prescription status, and conduct. In the United States, AAS were prescription drugs before federal Schedule III control began under the 1990 Act. They can still be prescribed legally for approved medical purposes, while unauthorized possession or distribution can violate federal and state law. Sports organizations operate under a separate rule system.

Myth 6: Historical medical use proves a modern bodybuilding claim

A drug’s former use for anemia, wasting, burns, or another condition does not prove that a nonmedical regimen is safe or effective. Historical practice must be interpreted in the context of the evidence, alternatives, product quality, and standards available at the time.

Steroid History Timeline

What the History of Anabolic Steroids Teaches Us

Steroid history is more than a sequence of names and scandals. A natural hormone became a purified chemical, a medicine, a family of modified drugs, a competitive tool, a controlled substance, an online commodity, and a symbol of disputed bodily ideals.

Each transition created a new context. Medical success encouraged experimentation; athletic gains created secrecy and pressure; prohibition stimulated testing and designer compounds; and the internet widened access while weakening the connection between a label and a verified product.

Precision makes that history useful. Testosterone emerged through collective work; Dianabol was influential but not first in every sense; Olympic prohibition happened in stages; and prescriptions, sports violations, and drug crimes are distinct. Those facts let readers recognize legitimate endocrine medicine without romanticizing nonmedical use.

Frequently Asked Questions

1. When were steroids invented?

Steroids are naturally occurring molecules, not a single invention. The modern AAS era began with androsterone’s isolation in 1931 and testosterone’s isolation and synthesis in 1935. Practical medicines and synthetic derivatives followed.

2. Who invented anabolic steroids?

No single person did. Berthold helped establish hormonal secretion; Butenandt isolated androsterone; an Organon team isolated and named testosterone; and the Butenandt-Hanisch and Ružička-Wettstein teams reported syntheses in 1935. Later chemists created synthetic derivatives.

3. When was testosterone discovered?

Testosterone was isolated and named in 1935 by researchers associated with Organon in the Netherlands. Separate German and Swiss teams reported chemical syntheses that same year. Earlier discoveries, particularly androsterone in 1931, paved the way.

4. What was the first anabolic steroid?

If the term includes the natural hormone, testosterone is the foundational anabolic-androgenic steroid and the first used clinically in modern form. If it means a marketed synthetic derivative designed to emphasize anabolic effects, compounds such as norethandrolone were among the earliest in the 1950s. The answer depends on the definition.

5. Why were anabolic steroids originally developed?

They were developed primarily for medicine. Testosterone was used to treat androgen deficiency and related endocrine conditions. Synthetic anabolic steroids were investigated for anemia, wasting, recovery from severe illness or injury, osteoporosis, and other conditions. Many historical uses were later narrowed, discontinued, or replaced.

6. Was Dianabol the first steroid?

No. Methandrostenolone, sold as Dianabol, was introduced in the United States in 1958. Testosterone medicines and other synthetic AAS already existed. Dianabol’s importance comes from its widespread early use among strength athletes and bodybuilders, not from being the first steroid.

7. Who was Dr. John Ziegler?

John Bosley Ziegler was an American physician associated with York Barbell and early U.S. strength-sport experimentation with testosterone and Dianabol. He helped connect pharmaceutical AAS with American weightlifting culture. He did not invent steroids or testosterone.

8. When did bodybuilders begin using steroids?

Testosterone and synthetic AAS entered strength sports during the 1950s, and use expanded in weightlifting and bodybuilding during the 1960s and 1970s. Exact first-use claims are difficult to prove because the practice was informal and poorly documented.

9. When were anabolic steroids banned from the Olympics?

The IOC prohibited anabolic steroids in 1974, with list and testing implementation developing through 1975. The 1976 Montreal Games featured the first Olympic testing for AAS. Using “1974–1976” captures the difference between the policy decision and operational testing.

10. When did steroids become controlled substances in the United States?

The Anabolic Steroids Control Act of 1990 placed named AAS in Schedule III of the federal Controlled Substances Act, with implementation in 1991. Congress expanded the framework in 2004 and again through the Designer Anabolic Steroid Control Act of 2014.

11. Were anabolic steroids used during World War II?

Claims that Nazi Germany created anabolic steroids or systematically gave testosterone to soldiers are widely repeated but not supported by strong, specific historical documentation. German scientists made important contributions to hormone chemistry in the 1930s. That documented scientific work should not be converted into an unverified wartime-doping narrative.

12. What are the most important dates in steroid history?

Key dates are 1849 (Berthold), 1931 (androsterone), 1935 (testosterone), 1958 (Dianabol), 1974–1976 (Olympic prohibition and testing), 1988 (Ben Johnson), 1990 (U.S. Schedule III law), 1999 (WADA), 2003 (THG), and 2004 and 2014 (U.S. legal expansions).

13. Why Is Steroid History Important?

Steroid History is important because it explains how naturally occurring hormones became prescription medicines, performance-enhancing substances, controlled drugs, and targets of modern anti-doping programs. This historical context helps readers distinguish legitimate medical treatment from nonmedical steroid use.

14. Where Does Steroid History Begin?

Steroid History begins with early experiments investigating how the testes influenced distant tissues. John Hunter’s transplantation experiment in 1786 and Arnold Adolph Berthold’s rooster studies in 1849 helped establish the scientific foundations of endocrinology.

15. What Role Did Testosterone Play in Steroid History?

Testosterone occupies a central position in Steroid History because its isolation, naming, and synthesis in 1935 created the foundation for modern androgen therapy and the later development of synthetic anabolic-androgenic steroids.

16. How Did Pharmaceutical Research Influence Steroid History?

Pharmaceutical research transformed Steroid History by producing testosterone esters, orally active compounds, and synthetic derivatives with different durations and pharmacological characteristics. These developments expanded legitimate medical treatment but eventually facilitated nonmedical athletic use.

17. How Did Competitive Sports Change Steroid History?

Competitive sports changed Steroid History when testosterone and synthetic anabolic steroids entered weightlifting and strength athletics during the 1950s. Their subsequent expansion into bodybuilding, track and field, football, and state-sponsored sports programs turned steroid use into an international controversy.

18. Why Is Dianabol Important in Steroid History?

Dianabol is important in Steroid History because it became one of the first oral anabolic steroids widely associated with weightlifters and bodybuilders after its U.S. introduction in 1958. However, Dianabol was not the first steroid or the first synthetic anabolic agent.

19. How Did Olympic Drug Testing Affect Steroid History?

Olympic drug testing marked a major turning point in Steroid History. The International Olympic Committee prohibited anabolic steroids in 1974, developed practical implementation during 1975, and conducted the first Olympic anabolic-steroid testing program at the 1976 Montreal Games.

20. How Did U.S. Legislation Change Steroid History?

U.S. legislation changed Steroid History when the Anabolic Steroids Control Act of 1990 placed named anabolic steroids in Schedule III of the Controlled Substances Act. Additional legislation in 2004 and 2014 expanded federal control over prohormones and designer steroids.

21. What Defines Modern Steroid History?

Modern Steroid History includes online underground markets, counterfeit products, social-media physique culture, designer anabolic agents, advanced mass-spectrometry testing, long-term metabolite detection, and the steroidal module of the Athlete Biological Passport.

Conclusion

Steroid history begins before the word existed and extends far beyond bodybuilding. It encompasses endocrinology, multinational hormone research, medical progress, Cold War sport, criminal law, analytical chemistry, and online appearance culture.

It is not a simple hero-or-villain story. Testosterone is an essential hormone and legitimate medicine for defined conditions. AAS also became tools of coercive state programs, concealed enhancement, unregulated commerce, and risky self-experimentation. Both realities belong in an accurate account.

For further reading, explore evidence-based guides to testosterone physiology, anabolic-steroid health effects, anti-doping rules, and the difference between medically supervised hormone treatment and nonmedical use.

References

Anawalt, B. D. (2019). Diagnosis and management of anabolic androgenic steroid use. The Journal of Clinical Endocrinology & Metabolism, 104(7), 2490–2500. https://doi.org/10.1210/jc.2018-01882

Catlin, D. H., Sekera, M. H., Ahrens, B. D., Starcevic, B., Chang, Y.-C., & Hatton, C. K. (2004). Tetrahydrogestrinone: Discovery, synthesis, and detection in urine. Rapid Communications in Mass Spectrometry, 18(12), 1245–1249. https://doi.org/10.1002/rcm.1495

Cussons, A. J., Bhagat, C. I., Fletcher, S. J., & Walsh, J. P. (2002). Brown-Séquard revisited: A lesson from history on the placebo effect of androgen treatment. Medical Journal of Australia, 177(11–12), 678–679. https://doi.org/10.5694/j.1326-5377.2002.tb05007.x

Fitch, K. D. (2008). Androgenic-anabolic steroids and the Olympic Games. Asian Journal of Andrology, 10(3), 384–390. https://doi.org/10.1111/j.1745-7262.2008.00377.x

Franke, W. W., & Berendonk, B. (1997). Hormonal doping and androgenization of athletes: A secret program of the German Democratic Republic government. Clinical Chemistry, 43(7), 1262–1279. https://pubmed.ncbi.nlm.nih.gov/9216474/

Freeman, E. R., Bloom, D. A., & McGuire, E. J. (2001). A brief history of testosterone. The Journal of Urology, 165(2), 371–373. https://doi.org/10.1097/00005392-200102000-00004

Hemmersbach, P. (2008). History of mass spectrometry at the Olympic Games. Journal of Mass Spectrometry, 43(7), 839–853. https://doi.org/10.1002/jms.1445

Kanayama, G., & Pope, H. G., Jr. (2018). History and epidemiology of anabolic androgens in athletes and non-athletes. Molecular and Cellular Endocrinology, 464, 4–13. https://doi.org/10.1016/j.mce.2017.02.039

Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502–521. https://doi.org/10.1038/bjp.2008.165

National Institute on Drug Abuse. (2024). Anabolic steroids and other appearance and performance enhancing drugs (APEDs). https://nida.nih.gov/research-topics/anabolic-steroids

Nieschlag, E., & Nieschlag, S. (2014). Testosterone deficiency: A historical perspective. Asian Journal of Andrology, 16(2), 161–168. https://doi.org/10.4103/1008-682X.122358

Nobel Prize Outreach. (n.d.). The Nobel Prize in Chemistry 1939. https://www.nobelprize.org/prizes/chemistry/1939/summary/

Pope, H. G., Jr., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014). Adverse health consequences of performance-enhancing drugs: An Endocrine Society scientific statement. Endocrine Reviews, 35(3), 341–375. https://doi.org/10.1210/er.2013-1058

U.S. Food and Drug Administration. (2025). Testosterone information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information

U.S. House of Representatives, Office of the Law Revision Counsel. (n.d.). 21 U.S.C. § 802—Definitions. https://uscode.house.gov/view.xhtml?req=granuleid

World Anti-Doping Agency. (2026). The prohibited list. https://www.wada-ama.org/en/prohibited-list

Author

Author: Dr. Daniel Martínez, MD, FACE — Board-Certified Endocrinologist, Senior Medical Director at Endocrine & Metabolic Research Institute, specializing in peptide therapeutics and hormone optimization with 18+ years clinical experience.

Medically reviewed by: Dr. James Thompson, MD — Board-Certified Endocrinologist, Fellow of the American College of Endocrinology, Clinical Associate Professor at University of Arizona College of Medicine.

Fact-checked by: Michael Roberts, MS — Pharmaceutical Sciences, Senior Research Associate specializing in analytical chemistry and peptide stability studies.

Last updated: September 8, 2026